Gonadal Function in Female Adolescent and Young Adult Survivors of Childhood Cancer
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose Childhood cancer survivors (CCSs) are at risk for premature ovarian insufficiency (POI). The aim of this study is to evaluate ovarian function and associated health outcomes in female adolescent and young adult survivors of childhood cancer.Materials and Methods Sixty-nine female CCSs were enrolled. Medical records of CCSs were retrospectively reviewed. The subjects were categorized into three groups according to follicular stimulating hormone (FSH) levels (cutoff, 12, 40 IU/L). Anti-müllerian hormone (AMH) level less than 1 ng/mL was considered low AMH level.Results Of 69 subjects, 14 (20.3%) had POI and 14 (20.3%) had FSH levels between 12 and 40 IU/L. Forty-one of 69 (59.4%) had normal FSH levels. Pelvic irradiation and stem cell transplantation (SCT) were more frequently performed in subjects with POI (p=0.001 and p < 0.001). AMH levels were remarkably low when FSH levels were over 12 IU/L (p < 0.001). In multivariate analysis, cyclophosphamide equivalent dose and SCT were significant treatment factors for developing low AMH levels (p=0.005 and p=0.002, respectively). Total, low-density lipoprotein cholesterol and triglyceride were significantly different in three groups according to FSH levels (p=0.047, p=0.030, and p=0.045). Z-score of femur neck bone mineral density was significantly reduced when FSH levels were increased (p=0.011).Conclusion Gonadal dysfunction is common in CCSs. Gonadal function was associated with a few treatment factors known to increase the risk of POI. Regular monitoring of gonadal function is needed for better health outcomes.
Abstract
Purpose Childhood cancer survivors (CCSs) are at risk for premature ovarian insufficiency (POI). The aim of this study is to evaluate ovarian function and associated health outcomes in female adolescent and young adult survivors of childhood cancer.Materials and Methods Sixty-nine female CCSs were enrolled. Medical records of CCSs were retrospectively reviewed. The subjects were categorized into three groups according to follicular stimulating hormone (FSH) levels (cutoff, 12, 40 IU/L). Anti-müllerian hormone (AMH) level less than 1 ng/mL was considered low AMH level.Results Of 69 subjects, 14 (20.3%) had POI and 14 (20.3%) had FSH levels between 12 and 40 IU/L. Forty-one of 69 (59.4%) had normal FSH levels. Pelvic irradiation and stem cell transplantation (SCT) were more frequently performed in subjects with POI (p=0.001 and p < 0.001). AMH levels were remarkably low when FSH levels were over 12 IU/L (p < 0.001). In multivariate analysis, cyclophosphamide equivalent dose and SCT were significant treatment factors for developing low AMH levels (p=0.005 and p=0.002, respectively). Total, low-density lipoprotein cholesterol and triglyceride were significantly different in three groups according to FSH levels (p=0.047, p=0.030, and p=0.045). Z-score of femur neck bone mineral density was significantly reduced when FSH levels were increased (p=0.011).Conclusion Gonadal dysfunction is common in CCSs. Gonadal function was associated with a few treatment factors known to increase the risk of POI. Regular monitoring of gonadal function is needed for better health outcomes.
참고문헌 (37)
- van Santen HM, "Hypogonadism in children with a previous history of cancer : endocrine management and follow-up", Horm Res Paediatr, 91, pp.93~103 (2019)
- Dwyer AA, "Transition in endocrinology : hypogonadism in adolescence", Eur J Endocrinol, 173, pp.R15~24 (2015)
- Chemaitilly W, "Premature ovarian insufficiency in childhood cancer survivors : a report from the St. Jude Lifetime Cohort", J Clin Endocrinol Metab, 102, pp.2242~2250 (2017)
- Clark RA, "Predicting acute ovarian failure in female survivors of childhood cancer : a cohort study in the Childhood Cancer Survivor Study(CCSS)and the St Jude Lifetime Cohort(SJLIFE)", Lancet Oncol, 21, pp.436~445 (2020)
- Hudson MM, "Long-term follow-up care for childhood, adolescent, and young adult cancer survivors", Pediatrics, 148, pp.e2021053127~ (2021)
- Andersen CY, "Concentrations of AMH and inhibin-B in relation to follicular diameter in normal human small antral follicles", Hum Reprod, 25, pp.1282~1287 (2010)
- Hagen CP, "Serum levels of anti-Mullerian hormone as a marker of ovarian function in 926 healthy females from birth to adulthood and in 172 Turner syndrome patients", J Clin Endocrinol Metab, 95, pp.5003~5010 (2010)
- Elchuri SV, "Anti-Mullerian hormone levels in American girls by age and race", ethnicity, 2015, pp.28, 189~193
- Kanakatti Shankar R, "Clinical utility of anti-Mullerian hormone in pediatrics", J Clin Endocrinol Metab, 107, pp.309~323 (2022)
- Lunsford AJ, "Antimullerian hormone as a measure of reproductive function in female childhood cancer survivors", Fertil Steril, 101, pp.227~231 (2014)
- Elchuri SV, "Low anti-Mullerian hormone in pediatric cancer survivors in the early years after gonadotoxic therapy", J Pediatr Adolesc Gynecol, 29, pp.393~399 (2016)
- Daan NM, "Cardiovascular risk in women with premature ovarian insufficiency compared to premenopausal women at middle age", J Clin Endocrinol Metab, 101, pp.3306~3315 (2016)
- Popat VB, "Bone mineral density in estrogen-deficient young women", J Clin Endocrinol Metab, 94, pp.2277~2283 (2009)
- Demeestere I, "Gonadotropin-releasing hormone agonist for the prevention of chemotherapy-induced ovarian failure in patients with lymphoma : 1-year follow-up of a prospective randomized trial", J Clin Oncol, 31, pp.903~909 (2013)
- Burger HG, "Prospectively measured levels of serum follicle-stimulating hormone, estradiol, and the dimeric inhibins during the menopausal transition in a population-based cohort of women", J Clin Endocrinol Metab, 84, pp.4025~4030 (1999)
- Green DM, "The cyclophosphamide equivalent dose as an approach for quantifying alkylating agent exposure : a report from the Childhood Cancer Survivor Study", Pediatr Blood Cancer, 61, pp.53~67 (2014)
- Kang MJ, "Body composition and bone density reference data for Korean children, adolescents, and young adults according to age and sex : results of the 2009-2010 Korean National Health and Nutrition Examination Survey(KNHANES)", J Bone Miner Metab, 34, pp.429~439 (2016)
- Chow EJ, "New agents, emerging late effects, and the development of precision survivorship", J Clin Oncol, 36, pp.2231~2240 (2018)
- Kremer LC, "A worldwide collaboration to harmonize guidelines for the long-term follow-up of childhood and young adult cancer survivors : a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group", Pediatr Blood Cancer, 60, pp.543~549 (2013)
- van Dorp W, "Recommendations for premature ovarian insufficiency surveillance for female survivors of childhood, adolescent, and young adult cancer : a report from the international late effects of childhood cancer guideline harmonization group in collaboration with the PanCareSurFup Consortium", J Clin Oncol, 34, pp.3440~3450 (2016)
- Green DM, "Ovarian failure and reproductive outcomes after childhood cancer treatment : results from the Childhood Cancer Survivor Study", J Clin Oncol, 27, pp.2374~2381 (2009)
- van Dorp W, "Reproductive function and outcomes in female survivors of childhood, adolescent, and young adult cancer : a review", J Clin Oncol, 36, pp.2169~2180 (2018)
- van der Kooi AL, "Longitudinal follow-up in female childhood cancer survivors : no signs of accelerated ovarian function loss", Hum Reprod, 32, pp.193~200 (2017)
- Choi R, "Reference intervals of anti-Mullerian hormone in Korean women", J Clin Lab Anal, 36, pp.e24525~ (2022)
- Hagen CP, "Individual serum levels of anti-Mullerian hormone in healthy girls persist through childhood and adolescence : a longitudinal cohort study", Hum Reprod, 27, pp.861~866 (2012)
- Anderson RA, "Cancer treatment and gonadal function : experimental and established strategies for fertility preservation in children and young adults", Lancet Diabetes Endocrinol, 3, pp.556~567 (2015)
- Thomas-Teinturier C, "Age at menopause and its influencing factors in a cohort of survivors of childhood cancer : earlier but rarely premature", Hum Reprod, 28, pp.488~495 (2013)
- Oktay K, "Fertility preservation in patients with cancer : ASCO clinical practice guideline update", J Clin Oncol, 36, pp.1994~2001 (2018)
- Su HI, "Modeling variation in the reproductive lifespan of female adolescent and young adult cancer survivors using AMH", J Clin Endocrinol Metab, 105, pp.2740~2751 (2020)
- Kim S, "Molecular mechanism and prevention strategy of chemotherapy-and radiotherapy-induced ovarian damage", Int J Mol Sci, 22, pp.7484~ (2021)
- Younis JS, "The impact of unilateral oophorectomy on ovarian reserve in assisted reproduction : a systematic review and meta-analysis", BJOG, 125, pp.26~35 (2018)
- Lehmann V, "Gonadal functioning and perceptions of infertility risk among adult survivors of childhood cancer : a report from the St Jude Lifetime Cohort Study", J Clin Oncol, 37, pp.893~902 (2019)
- van der Perk ME, "Effect of genetic variation in CYP450 on gonadal impairment in a European cohort of female childhood cancer survivors, based on a candidate gene approach : results from the PanCareLIFE Study", Cancers(Basel), 13, pp.4598~ (2021)
- van der Kooi AL, "Genetic variation in gonadal impairment in female survivors of childhood cancer : a PanCareLIFE study protocol", BMC Cancer, 18, pp.930~ (2018)
- Jin Hye Young, "Low bone mineral density in children and adolescents with cancer", Annals of Pediatric Endocrinology & Metabolism, 25(3), pp.137~144 (2020), 대한소아내분비학회[DOI]
- Almeida M, "Estrogens and androgens in skeletal physiology and pathophysiology", Physiol Rev, 97, pp.135~187 (2017)
- Fahed AC, "Connecting the lines bet-ween hypogonadism and atherosclerosis", Int J Endocrinol, 2012, pp.793953~ (2012)